Forbes shares that the first attempt for Sanofi Aventis, a bid of $18.5 billion, was rejected by Genzyme. Genzyme believes that the company should be valued at a much higher price. The bid from Sanofi Aventis has been expected. Genzyme is facing a few manufacturing issues when inspectors found particles of trash and other particles in the medication manufactured at several plants. Stock prices of Genzyme, however, continue to rise today, showing that investors believe that Sanofi Aventis will come back with a higher bid.
|
Share this article with your social network, just click below to share now!
|
|
|
The global synthetic biology market is supposed to reach $13.4 billion by 2019. A recent study from Transparency Market Research shows that...
Oren Levy from Karp Lab gave an excellent talk called “MSCs on Steriods” last month at Biotech Week Boston. Oren's research focus is &q...
If you blink you will most likely miss some major design, invention or discovery in the robotics industry. The future is definitely here, an...
No comments :
Post a Comment